



(Translation)

Minutes of the 2025 Annual General Meeting of Shareholder

Safe Fertility Group Public Company Limited

Date, time, and venue of the Meeting

The 2025 Annual General Meeting of Shareholders (“**the Meeting**”) was convened on Tuesday 29 April 2024, at 10:00 AM, via electronic means only via electronic means (E-AGM) only according to the Emergency Decree on Electronic Meeting B.E. 2563 (2020). The Meeting was broadcast from conference of Safe Fertility Group Public Company Limited (“**the Company**”), No. 496, 498, 500, 502 Amarin Plaza Building, 17th Fl., Ploenchit Rd., Lumpini, Pathumwan, Bangkok.

The Meeting convened at 10:00 a.m.

Ms. Thitaree Wongsawangpanit, assigned by the Company to function as the Master of Ceremony of the Meeting (“**the MC**”), welcomed shareholders to the 2025 Annual General Meeting of Shareholders of the Company which the meeting of the Board of Directors resolved to hold via electronic means (E-AGM) only according to the Emergency Decree on Electronic Meeting B.E. 2563 (2020) and other related laws and regulations. The meeting was held and broadcast live from the Company’s headquarters meeting room via the electronic meeting control system provided by OJ International Co., Ltd.

Then, **the MC** announced the number of shareholders in attendance when the Meeting convened with 9 shareholders attending in person and 74 shareholders attending by proxy, a total of 83 shareholders, representing a total of 257,701,485 shares, equivalent to 84.7848% of all of the Company’s total paid-up ordinary shares 303,947,800 shares. As the number of shareholders exceeded 25 shareholders and the total shares represented more than one-third of the total paid-up ordinary shares, the Meeting was constituted with a quorum in accordance with the law and the Company’s Articles of Association.

To ensure that the Meeting was convened smoothly and complies with the principles of good corporate governance, the MC explained about the Meeting’s procedures, methods for voting and vote counting and how to express opinions or ask questions as follows.

- The annual general meeting of shareholders has only a normal agenda by considered according to the agenda specified in the meeting invitation letter and there will be no additional agenda items to consider other matters.
- In each agenda, the Company will present information and provide an opportunity for shareholders to ask questions before voting. Shareholders must be present the meeting until the end of the agenda and must vote on each agenda before the closing of voting on such agenda.
- When voting at the Meeting, every shareholder has votes equal to the number of shares which he/she held and register to attend the meeting. One share equals one vote. A shareholder may cast votes of approval or disapproval or abstention on each agenda. If any shareholder has special stakes in any topic, that shareholder will have no right to vote on that topic except in the case of voting to elect a director. In cases where votes are tied, the Chairman will cast another vote as the deciding vote.
- For shareholders proxy to others to attend the meeting and directed proxies to vote according to shareholders' intentions, the Company recorded the votes of approval or disapproval, or abstention recorded in advance during registration to attend the Meeting according to the stated in the proxy form for voting according to the agenda.
- The method for voting via electronic means
 - Shareholders who wish to vote must be cast in the E-Voting system by clicking on the E-Voting button. For attendees using mobile devices or tablets, please switch from the Zoom program back to the Chrome program to vote in the E-Voting menu.
 - After that, a new window will appear showing various agendas. Shareholders can choose the agenda to vote on and press the voting button as desired. The system will display a total of 3 buttons: "Approval", "Disapproval" and "Abstention". An agenda for acknowledgement will not be able to vote
 - When you press to select voting, the system will pop up a small window asking to confirm your vote. Press OK to confirm your vote.
 - When you have finished voting, please return to the E-meeting window (Zoom program) to continue viewing the video and audio of the meeting.
 - Voting can be changed until notification of the closing of voting for each agenda. If the agenda has already been closed for voting, shareholders will not be able to vote or change the vote.
 - For voting. The Company will allow shareholders 1 minute time to cast their vote per agenda item.
 - Shareholders who do not vote on any agenda are considered to have voted in approval.

- Shareholders must be present the meeting until the end of the agenda and must vote on each agenda before the closing of voting on such agenda. In the case that shareholders confirm leaving the meeting or log out without voting in advance before closing voting on any agenda, shareholders' votes will not be counted as a quorum and votes were not counted in that agenda. However, leaving the meeting on any agenda will not deprive the shareholder or proxy of the right to return to the meeting and vote on the next agenda.
- Votes counting for agendas at the 2025 Annual General Meeting of Shareholders are divided into the following two types:
 - Agenda item 4, 5, 6 and 8 requires a resolution in approval with a majority vote of the shareholders who attended the Meeting and exercised their voting rights. With respect to Agenda item 6 regarding the election of directors to replace the directors retiring by rotation, shareholders would be asked to cast their votes for each candidate on an individual basis, in order to be consistent with guidelines on the Annual General Meeting Quality Assessment.
 - Agenda item 7 requires a resolution in approval not less than two-thirds (2/3) of the shareholders who attended the Meeting and exercised their voting rights.
 - Agenda item 1, 2 and 3 no voting due to agenda for acknowledgment.
- To count votes, votes of disapproval or abstention, as well as the votes on invalid ballots (if any) would then be deducted from the total number of votes of the shareholders present at the Meeting, and the remaining numbers would be treated as votes for the approval of that agenda item. Votes cast by proxy grantors in proxy are counted and recorded in advance during registration to attend the Meeting.
- Ballots are invalid in cases where the shareholder appoints a proxy and specifies his votes in advance, but his declared intention is unclear, for example, they specify to vote in more than one box, and PTT is unable to verify such intention to vote of the shareholder.
- The method for asking questions and express opinions via electronics means. Before voting on each agenda, the Chairman will provide an opportunity for shareholders to asking questions and express opinions relevant to such agenda, through the following two channels:

Channel 1 Inquiry through Text Message. It can be done as follows

 1. Go to the Q&A menu in the Zoom program to type a message.
 2. Press the Enter button to send a message into the system.

Channel 2: Inquiry through Conversation. It can be done as follows

1. Go to the Participant menu at the bottom and press the Raise Hand button.
 2. When the MC calls out your name, the staff will turn on the microphone for you to inquire. You must press Unmute and turn on the microphone on your device. In the case that shareholders are unable to speak through the microphone (within 1 minute), please type your questions via the Q&A channel instead so that the MC can read the questions to the meeting on your behalf.
- In asking each question both through typing a message or through conversation, attendees required to provide their name, surname and state whether they are a shareholder or a proxy prior to asking a question in order for the meeting minutes to be recorded completely and accurately. The Company reserves the right to answer only questions related to the agenda that has voting only. As for unrelated questions, they will be answered in Agenda item 7: Other matters.
 - The Company provide an opportunity for attendees to submit questions in each agenda. In the event that there are no attendees inquire within 2 minutes, the Company will continue the meeting. If shareholders have additional questions, you can type in your questions via Chat and the staff will read your questions later.
 - In case several questions, the Company reserves their right to choose answers as appropriate in order to preserve time. In any case, the Company reserves their right to edit out the visual and audio of any shareholder who asks a question or expresses an opinion which is impolite, defamatory, or violates the laws, or violates other's rights, disrupting the meeting or causing disruption for other attendees.

The MC introduced the Company's Independent Directors, Directors, Top Executives and Auditors as follow.

Directors (the directors attending the Meeting accounted for 100 percent)

- | | | | |
|----|---------------|-----------------|--|
| 1. | Mr. Amnuay | Preemonwong | Independent Director / Chairman of Board of Director / Audit Committee |
| 2. | Mr. Jirayut | Rungsrithong | Independent Director / Chairman of Audit Committee / Nomination and Remuneration Committee |
| 3. | Mr. Gran | Chayavichitsilp | Independent Director / Audit Committee / Chairman of Nomination and Remuneration Committee |
| 4. | Mr. Yuttapong | Ma | Director |
| 5. | Mr. Wiwat | Quangkananurug | Director / Nomination and Remuneration Committee / Chief Executive Officer |

6. Mrs. Parinyarat Quangkananurug Director / Managing Director
7. Miss Chanida Pattanotai Director / Chief Financial Officer
Auditor from PricewaterhouseCoopers ABAS Ltd.
 1. Mr. Krit Chatchavalwong
 2. Mr. Prakasit Singkhaw

With respect to the documents used for the Meeting today, the Company had published such documents on its website and notified the publication to the Stock Exchange of Thailand on 31 March 2025 so that shareholders have time to study the meeting information in advance.

The Company has sent a link to attend the meeting with a manual for E-AGM, voting and vote counting methods and how to express opinions or ask questions via email to shareholders. In cases where shareholders encountered problems when accessing the Meeting system or the voting system, please follow meeting instructions that the company has informed. During the meeting, the Company has recorded the meeting in the form of image and video media, including the audio of the meeting of shareholders for publicizing the meeting Through the company's website and other communication channels of the Company. If you do not want to publish, please report to email: investorrelations@safefertilitygroup.com

Mr. Amnuay Premonwong, the Chairman of the Board of Directors, presided as the Chairman of the Meeting (the Chairman) then opened the Meeting and assigned the MC and Miss Tasanun Chuiklom, the Company Secretary, to conduct the Meeting according to the following agendas:

Agenda item 1 **Matters informed by the Chairman**

The Chairman informed the Meeting that Admiral Pichet Tanaset had resigned from his position as a Director due to personal commitments, effective from 1 February 2025. The Board of Directors will consider and nominate a qualified individual to fill the vacancy. The Company will inform the Stock Exchange of Thailand and shareholders accordingly.

Agenda item 2 **To acknowledge the Minutes of the 2024 Annual General Meeting of Shareholders**

The Company Secretary informed the Meeting that the 2024 Annual General Meeting of Shareholders was held on Friday, 26 April 2024. The Company completed the minutes of the meeting within 14 days from the meeting date and submitted them to the Stock Exchange of Thailand, as well as published them on the Company's website on Friday, 10 May 2024. A copy of the meeting minutes has also been sent to shareholders along with the invitation of the Meeting.

The Board of Directors considered that the recording of the minutes of the 2024 Annual General Meeting of Shareholders has been made correctly and completely, and no shareholders proposed any amendments to the minutes of the meeting.

The proposal for consideration under this agenda is to propose the shareholder's meeting acknowledge the Minutes of the 2024 Annual General Meeting of Shareholders.

Then provide an opportunity for shareholders to inquiries or express opinions and asked **the MC** to explain the process for asking a question. Questions and suggestions that were raised subsequently were summarized as follows.

None of shareholder inquiries or express opinions, **the MC** informed that Agenda 2 is an agenda for acknowledgement. Therefore, no voting on this agenda.

The Meeting's Resolution

The Shareholder's Meeting acknowledged the Minutes of the 2024 Annual General Meeting of Shareholders.

Agenda item 3 To acknowledge the Company's operating results for the year 2024

The Company Secretary informed the Meeting that the Company has summarized its past performance and significant changes occurred in 2024, with details as shown in the Annual Registration Statement/Annual Report 2024 (Form 56-1 One Report) which has been sent to shareholders along with the invitation of the Meeting and invited **Mr. Wiwat Quangkananrug, Chief Executive Officer**, to summarize the Company's performance highlights in 2024 to the shareholders for acknowledgement. And next, **Ms. Chanida Pattanotai, Chief Financial Officer** summarized the Company's operating results for the year 2024 to the shareholders for acknowledgement.

Mr. Wiwat Quangkananrug, Chief Executive Officer, reported the summarize of the Company's performance highlights in 2024 as follows:

For the year 2024, the Company experienced a slight decline in revenue, approximately 2%, which was lower than expected. This was due to several factors, the first being the impact of the Year of the Dragon, during which many patients sought treatment and planned pregnancies. Consequently, in the following Year of the Snake, there was a significant drop in patient visits. In addition, the economic situation and concerns over travel safety led to a decrease in medical tourism. As a result, the Company's overall performance declined. The CFO will report the details of the operating results later.

As previously informed at the 2024 Annual General Meeting of Shareholders, the Company planned to implement a new chromosome screening technology called PGTSeqA, developed by JUNO Genetics, a leading embryo testing service provider based in the United States. This technology represents an innovation in the field, offering significantly improved diagnostic accuracy, which increases the chances of pregnancy and reduces miscarriage rates. The turnaround time for results is also faster. Moreover, the system is capable of processing a higher volume of embryos, enabling the Company to serve more clients and achieve economies of scale. The impact on revenue from the adoption of this technology is expected to be seen in 2025, as external client services commenced around December 2024 and have so far received positive feedback.

For future plans and development, the Company aims to achieve sustainable growth across all business segments, including fertility clinics, embryo chromosome screening, non-invasive prenatal testing (NIPT), and wellness services. The Company is also exploring various business expansion opportunities both domestically and internationally. Domestically, the Company has established partnerships with hospitals and obstetrics-gynecology clinics. Internationally, the Company has formed collaborations with hospitals, clinics, and agencies to attract more patients to use its services.

In addition, the Company places strong emphasis on anti-corruption efforts. It has established policies and procedures to serve as practical guidelines for preventing and combating corruption within the organization. The Board of Directors and management are responsible for raising awareness of the detrimental effects of corruption and fostering the right values to ensure effective anti-corruption measures. The Company also communicates these policies to employees and requires adherence, while making them publicly available on the Company's website under the Corporate Governance section. In 2024, there were no complaints or incidents related to corruption.

Then, **Ms. Chanida Pattanotai, Chief Financial Officer**, reported a summary of the Company's operating results for the year 2024 as follows:

In 2024, the Company enhanced its ESG (Environmental, Social, and Governance) initiatives with key actions in each area as follows:

Economic and Governance: The Company expanded its medical services to both private and public hospitals and strengthened its health partnerships domestically and internationally, reinforcing its position within the regional healthcare network.

- Developed PGTseq-A, an advanced embryo screening technology that enhances pregnancy success rates.

- Implemented data security measures in compliance with the Personal Data Protection Act (PDPA) as well as ISO 27001 and ISO 27701 standards.
- Enhanced its Risk Governance Framework to ensure systematic risk management, including the development of a Risk Register and Risk Heat Map to monitor and mitigate potential risks.
- Conducted training on the Code of Conduct and established secure and transparent whistleblowing channels.

Environmental: The Company implemented measures to minimize environmental impact through waste management and resource conservation, including:

- A 4.16% reduction in infectious waste compared to the baseline year.
- A 0.02% decrease in water consumption compared to 2023.
- Initiated measurement of greenhouse gas (GHG) emissions as a foundation for developing a future carbon reduction plan.

Social: The Company focused on human capital development through professional and specialized technological training, with key initiatives including:

- A 104.55% increase in the number of employees receiving professional certifications compared to the previous year.
- An annual seminar was held to strengthen organizational engagement, with 97.77% employee participation.
- A happiness survey covering 11 dimensions revealed an average employee satisfaction score of 66.84%.
- In terms of employee health, 100% of eligible staff completed their annual health check-ups, and wellness was promoted through fitness-related benefits.
- A total of 17 CSR activities were organized, focusing on education, healthcare, and sustainable community development.

For the fiscal year 2024, the Company reported its financial results to the Stock Exchange of Thailand on 20 February 2025. The Group recorded total revenue from sales and services of THB 830.13 million, representing a slight decrease of 2.18% compared to the previous year. However, over the past three years, the Company has maintained an average annual growth rate of 14.04%. The primary revenue contributor was Safe Fertility Group Public Company Limited, which generated THB 641.95 million (76.08% of total group revenue) from comprehensive fertility treatment services. The two subsidiaries contributed as follows: 1) Next Generation Genomic Co., Ltd. (NGG) – a provider

of genetic testing services for embryos and fetuses – reported revenue of THB 169.48 million, accounting for 20.08% of the Group's total revenue. 2) Safe Wellness Co., Ltd., which provides aesthetics and wellness services, generated revenue of THB 18.70 million, representing 2.21% of the Group's total revenue.

Regarding profitability, the Group reported a gross profit of THB 457.28 million, representing a gross profit margin of 55.10%. The Company successfully maintained a high level of gross profit margin. Operating profit stood at THB 279.26 million, with an EBITDA margin of 33.10%, showing a slight decrease. The main increase in expenses in 2024 was primarily related to marketing activities. The Company implemented a more comprehensive and multi-channel marketing strategy to reach both domestic and international customers, aiming to raise awareness and enhance visibility. As a result, marketing expenses increased notably in 2024, with anticipated returns expected to be reflected in 2025. Net profit was THB 167.09 million, representing a net profit margin of 19.80%.

As of 31 December 2024, the Company had total assets of THB 2,007 million, shareholders' equity of THB 1,790 million, and total liabilities of THB 217 million. The Company had no borrowings from financial institutions; the liabilities mainly consisted of trade payables and employee benefit obligations in accordance with accounting standards requiring provision. Therefore, the interest-bearing debt-to-equity ratio remained low at 0.04 times.

The return on assets (ROA) was 8.21%, and the return on equity (ROE) was 9.55%

The Company Secretary informed the Meeting that proposals for consideration under this agenda to propose the shareholder's meeting acknowledge the Company's operating results for the year 2024 as reported.

Then provide an opportunity for shareholders to inquiries or express opinions and asked the MC to explain the process for asking a question. Questions and suggestions that were raised subsequently were summarized as follows.

None of shareholder inquiries or express opinions, **the MC** informed that Agenda item 3 is an agenda for acknowledgement. Therefore, no voting on this agenda.

The Meeting's Resolution

The Shareholder's Meeting acknowledged the Company's operating results for the year 2024.

Agenda item 4 **To consider and approve the financial statements for the year ended 31 December 2024**

The Company Secretary invited **Ms. Chanida Pattanotai, Chief Financial Officer**, to explain the Company's financial statements for the year 2024 to shareholders for acknowledgement as follows.

Statement of financial position

As of December 31, 2024, the Company's total assets increased from the previous year to THB 2,007 million. Total liabilities decreased from the previous year to THB 217 million, while shareholders' equity increased from the previous year to THB 1,790 million.

Statement of Comprehensive Income

As previously reported under an earlier agenda item, the Company recorded revenue from sales and services in 2024 of THB 830 million, slightly decrease. The net profit attributable to the owners of the parent was THB 167 million. The separate financial statements showed a consistent trend with the consolidated financial statements.

Statement of Cash Flow

In 2024, the Company generated THB 239.90 million in cash from operating activities. Cash used in investing activities amounted to THB 343.70 million, primarily from short-term liquidity management investments in the money market. Cash used in financing activities was THB 56.10 million, mainly from dividend payments. As a result, cash and cash equivalents decreased by Baht 159.90 million. Combined with the beginning cash balance of THB 1,251.20 million, the ending cash balance stood at THB 1,091.12 million.

The Company Secretary informed the Meeting that proposals for consideration under this agenda to propose the shareholder's meeting approve the financial statements for the year ended 31 December 2024 which have been audited by the auditor and reviewed by the Audit Committee. The board has also endorsed the statements.

Then, provide an opportunity for shareholders to inquiries or express opinions and asked **the MC** to explain the process for asking a question.

None of shareholders inquired or commented further, and therefore, **the MC** asked the shareholders to cast vote on this agenda item via e-Voting within a timeframe of 1 minute.

This agenda requires a resolution in approval with a majority vote of the shareholders who attended the Meeting and exercised their voting rights.

The Meeting's Resolution

The Meeting resolved to approve the financial statements for the year ended 31 December 2024 which have been audited by the auditor, reviewed by the Audit Committee and the Board has also endorsed the statements by the unanimous votes of the shareholders who attended the Meeting and were eligible to vote as follows:

Approved	257,748,285	votes	or	100.0000%
Disapproved	-	votes	or	-
Abstained	-	votes	or	-
Voided Ballots	-	votes	or	-

Agenda items 5 To consider and approve the dividend payment for the operation results for the year 2024

The Company Secretary invited **Ms. Chanida Pattanotai, Chief Financial Officer**, to explain details of dividend payment for the 2024 performance to shareholders as follows.

The Company has a policy to distribute dividends to shareholders at least 50% of the net profit based on the separate financial statements, after deducting corporate income tax, legal reserves, and other reserves (if applicable). The Board of Directors will approve dividend payment by considering various factors, primarily for the benefit of shareholders. Dividend payment will not have a significant impact on the Company's regular operations as the Board of Directors considers appropriate.

From the Company's operating results as shown in the financial statements ending 31 December 2024, the Company had a net profit for separate financial statement of THB 189.13 million. Therefore, we would like to propose to pay dividends for the operating results from 1 January 2024 to 31 December 2024 at the rate of THB 0.62 per share, totaling THB 188.45 million, representing a dividend payout ratio of 99.64%. The Record Date to determine the name of shareholders who are entitled to receive the dividend has been set on 9 May 2025, and the dividend will be paid on 23 May 2025, when approval from the 2025 annual general meeting of shareholders

The said dividend payment is in line with the Company's dividend payment policy and does not affect liquidity and the Company's capital structure by taking into account the need for money according to various investment plans

The Company Secretary informed the Meeting that proposals for consideration under this agenda to propose the shareholder's meeting approve to pay dividends for the operating results for the year 2024 at the rate of THB 0.62 per share, totaling THB 188.45 million. The Record Date to determine the name of shareholders who are entitled to receive the dividend has been set on 9 May 2025, and the dividend will be paid on 23 May 2025.

Then, provide an opportunity for shareholders to inquiries or express opinions and asked **the MC** to explain the process for asking a question.

None of shareholders inquired or commented further, and therefore, **the MC** asked the shareholders to cast vote on this agenda item via e-Voting within a timeframe of 1 minute.

This agenda requires a resolution in approval with a majority vote of the shareholders who attended the Meeting and exercised their voting rights.

The Meeting's Resolution

The Meeting resolved to approved to pay dividends for the operating results for the year 2024 at the rate of THB 0.62 per share, totaling THB 188.45 million. The Record Date to determine the name of shareholders who are entitled to receive the dividend has been set on 9 May 2025, and the dividend will be paid on 23 May 2025. The shareholders' meeting approved this agenda at the unanimous votes of the shareholders who attended the meeting and were eligible to vote as follows:

Approved	257,748,285	votes	or	100.0000%
Disapproved	-	votes	or	-
Abstained	-	votes	or	-
Voided Ballots	-	votes	or	-

Agenda items 6 To consider and approve the appointment of directors in replacement of those who must retire by rotation

The Company Secretary informed the Meeting that the Company's Articles of Association, specify as follows: "At every Annual General Meeting of Shareholders, at least one-third (1/3) of the directors shall retire or the number of directors closest to one-third (1/3) shall retire. The retired directors may be re-elected". At the 2025 Annual General Meeting of Shareholders, 3 directors shall retire by rotation as follow.

- | | | |
|------------------|----------------|---|
| 1. Mr. Gran | Chayavijitsilp | Independent Director / Audit Committee
Chairman of Nomination and Remuneration Committee |
| 2. Mr. Yuttapong | Ma | Director |
| 3. Ms. Chanida | Pattanotai | Director |

In order to comply with the principles of good corporate governance and for transparency, therefore, all 3 directors whose terms expired who are considered stakeholders in this agenda leave the meeting until the consideration of this agenda is completed.

The Company Secretary explained the Meeting that the Company provided the shareholders with the opportunity to nominate any candidate to be appointed as a director in advance during 15 November 2024 to 31 December 2024, none of the shareholders has nominated any candidate for consideration.

The Nomination and Remuneration Committee has considered and selected qualified individuals to be nominated as directors to replace directors who retire by rotation, based on their knowledge, skills, experience, and expertise that are beneficial and appropriate for the Company's business operations through a process of careful consideration in order to ensure compliance with the criteria for nomination and appointment of the Company's directors. The independence of independent directors is also considered, concerning their abilities to perform their duties, including that such independent directors must be able to provide opinions on an independent basis in accordance with the relevant rules and regulations.

The Nomination and Remuneration Committee, excluding the nominated directors, has considered and concluded that the 3 directors who retire by rotation possess the knowledge, capability, and experience beneficial to the Company's business operations. They have contributed significantly to the Company and have performed their duties effectively as members of the Board of Directors and various sub-committees. Therefore, it is proposed that the following 3 directors namely: 1) Mr. Gran Chayavijitsilp 2) Mr. Yuttapong Ma and 3) Ms. Chanida Pattanotai to be re-elected as the Company's director for another term of duty, including positions in various sub-committees. In addition, it is proposed that Mr. Gran Chayavijitsilp be appointed as an Independent Director.

The Board of Director Meeting, excluding stakeholder directors, has carefully reviewed and approved the proposal of the Nomination and Remuneration Committee

In this regard, the Company has enclosed a brief biography of the nominated persons to the invitation of the Meeting.

The proposal for consideration under this agenda is to propose the shareholders' meeting re-elect the following 3 directors who retire by rotation namely: 1) Mr. Gran Chayavijitsilp 2) Mr. Yuttapong Ma and 3) Ms. Chanida Pattanotai to be the Company's directors for another term, including positions in various sub-committees. In addition, it is proposed that Mr. Gran Chayavijitsilp be appointed as an Independent Director.

Then, provide an opportunity for shareholders to inquiries or express opinions and asked **the MC** to explain the process for asking a question.

None of shareholders inquired or commented further, and therefore, **the MC** asked the shareholders to cast vote on this agenda item via e-Voting within a timeframe of 1 minute.

This agenda requires a resolution in approval with a majority vote of the shareholders who attended the Meeting and exercised their voting rights.

The Meeting's Resolution

The shareholder's meeting resolved to approve the re-election of the 3 directors who retired by rotation namely 1) Mr. Gran Chayavijitsilp 2) Mr. Yuttapong Ma and 3) Ms. Chanida Pattanotai to be the Company's director for another term of duty at the majority vote of the shareholders who attended the meeting and were eligible to vote as follows:

(1) Mr. Gran Chayavijitsilp Independent Director / Audit Committee /
Chairman of Nomination and Remuneration Committee

Approved	256,891,185	votes	or	99.6675%
Disapproved	-	votes	or	-
Abstained	857,100	votes	or	0.3325%
Voided Ballots	-	votes	or	-

(2) Ms. Chanida Pattanotai Director

Approved	256,080,725	votes	or	99.3530%
Disapproved	-	votes	or	-
Abstained	1,667,560	votes	or	0.6470%
Voided Ballots	-	votes	or	-

The shareholders' meeting approved this agenda at the unanimous votes of the shareholders who attended the meeting and were eligible to vote as follows:

(3) Admiral Pichet Tanaseth Director

Approved	257,748,285	votes	or	100.00%
Disapproved	-	votes	or	-
Abstained	-	votes	or	-
Voided Ballots	-	votes	or	-

After the voting for the appointment of the directors to replace those retiring by rotation was completed, **the MC** invited the newly appointed directors to re-enter the meeting room.

Agenda item 7 **To consider and approve the remuneration of the Board of Directors and Sub-committee for the year 2025**

The Company Secretary informed the Meeting that the Nomination and Remuneration Committee considered the remuneration of the Board of Directors and Sub-committees under the criteria and policy on the determination of remuneration for the Board of Directors and Sub-committees by using important factors such as;

- Appropriate and consistent with the duties and responsibilities of the directors.
- The Company's financial status and performance
- Remuneration rate of companies in the same business group or industry

The Nomination and Remuneration Committee therefore proposes that the remuneration for the directors and members of various sub-committees for the year 2025 be set at the same rate as in 2024, with a total budget not exceeding THB 3 million. The details are as follows:

Remuneration	2024	2025
Board of Director		
<u>Monthly fee</u>	Baht/Person/Month	Baht/Person/Month
- Chairman	40,000	40,000
- Non-executive Director	22,500	22,500
<u>Attendance fee</u>	Baht/Person/Time	Baht/Person/Time
- Chairman	30,000	30,000
- Director	20,000	20,000
Audit Committee		
<u>Attendance fee</u>	Baht/Person/Time	Baht/Person/Time
- Chairman	30,000	30,000
- Member	25,000	25,000
Nominating and Remuneration Committee		
<u>Attendance fee</u>	Baht/Person/Time	Baht/Person/Time
- Chairman	15,000	15,000
- Member	10,000	10,000

The proposal for consideration under this agenda is to propose the shareholders' meeting approve the determination of remuneration for the Board of Directors and Sub-committees for the year 2025 at the same rate as in 2024, with a total budget not exceeding THB 3 million, as detailed in the proposal.

Then, provide an opportunity for shareholders to inquiries or express opinions and asked **the MC** to explain the process for asking a question.

None of shareholders inquired or commented further, and therefore, **the MC** asked the shareholders to cast vote on this agenda item via e-Voting within a timeframe of 1 minute.

This agenda requires a resolution in approval not less than two-thirds (2/3) of the shareholders who attended the Meeting and exercised their voting rights.

The Meeting's Resolution

The shareholder's meeting resolved to approve the determination of remuneration for the Board of Directors and Sub-committees for the year 2025 at the same rate as in 2024, with a total budget not exceeding THB 3 million as proposed by the Nomination and Remuneration Committee and concurred by the Board of Directors. The details are as follows:

Remuneration	2025
Board of Director	
<u>Monthly fee</u>	Baht/Person/Month
- Chairman	40,000
- Non-executive Director	22,500
<u>Attendance fee</u>	Baht/Person/Time
- Chairman	30,000
- Director	20,000
Audit Committee	
<u>Attendance fee</u>	Baht/Person/Time
- Chairman	30,000
- Member	25,000
Nominating and Remuneration Committee	
<u>Attendance fee</u>	Baht/Person/Time
- Chairman	15,000
- Member	10,000

The shareholders' meeting approved this agenda at the unanimous votes of the shareholders who attended the meeting and were eligible to vote as follows:

Approved	257,748,285	votes	or	100.0000%
Disapproved	-	votes	or	-
Abstained	-	votes	or	-
Voided Ballots	-	votes	or	-

Agenda item 8 **To consider and approve the appointment of auditor and audit fee for the year 2025**

The Company Secretary informed the Meeting that the Audit Committee considered the qualifications and experience of auditors from PricewaterhouseCoopers ABAS Company Limited, the Company's auditor for the year 2024, is of the opinion that perform duties responsibly, able to review and audit financial statements to be completed on time, be independent in auditing and expressing opinions on the Company's financial statements, as well as, being a company that is internationally recognized. Therefore, in 2025, it is proposed to appoint an auditor from PricewaterhouseCoopers ABAS Company Limited to be the auditor of the company and its subsidiaries. The names are as follows:

- | | | |
|-----------------|----------------|---------------------------|
| 1. Mr. Krit | Chatchavalwong | CPA Registration No. 5016 |
| 2. Ms. Sanicha | Akarakittilap | CPA Registration No. 8470 |
| 3. Ms. Nopanuch | Apichatsatien | CPA Registration No. 5266 |

And determine an audit and review fee of the financial statements of the Company and its subsidiaries for 2025 at total amount is THB 4,650,000 with details as follows:

Company	Audit fee		
	2024	2025	%Increase
Safe Fertility Group Public Company Limited	2,765,000 Baht	2,765,000 Baht	-
Next Generation Genomic Company Limited	1,365,000 Baht	1,365,000 Baht	-
Safe Wellness Company Limited	520,000 Baht	520,000 Baht	-

The Company Secretary informed the Meeting that proposals for consideration under this agenda to propose the shareholders' meeting approve the appointment of auditors from PricewaterhouseCoopers ABAS Company Limited as follows:

- | | | |
|-----------------|----------------|---------------------------|
| 1. Mr. Krit | Chatchavalwong | CPA Registration No. 5016 |
| 2. Ms. Sanicha | Akarakittilap | CPA Registration No. 8470 |
| 3. Ms. Nopanuch | Apichatsatien | CPA Registration No. 5266 |

And determine an audit and review fee of the financial statements of the Company and its subsidiaries for the year 2025 at total amount is THB 4,650,000, as detailed in the proposal.

Then, provide an opportunity for shareholders to inquiries or express opinions and asked **the MC** to explain the process for asking a question.

None of shareholders inquired or express opinions, and therefore, **the MC** asked the shareholders to cast vote on this agenda item via e-Voting within a timeframe of 1 minute.

This agenda requires a resolution in approval with a majority vote of the shareholders who attended the Meeting and exercised their voting rights.

The Meeting's Resolution

The shareholder's meeting resolved to approve the appointment of auditors from PricewaterhouseCoopers ABAS Company Limited as follows:

- | | | |
|-----------------|----------------|---------------------------|
| 1. Mr. Krit | Chatchawalwong | CPA Registration No. 5016 |
| 2. Ms. Sanicha | Akarakittilap | CPA Registration No. 8470 |
| 3. Ms. Nopanuch | Apichatsatien | CPA Registration No. 5266 |

And approved the audit and review fees for the financial statements of the Company and its subsidiaries for the year 2025 in the total amount of Baht 4,650,000, as duly considered by the Audit Committee and approved by the Board of Directors.

The shareholders' meeting approved this agenda at the unanimous votes of the shareholders who attended the meeting and were eligible to vote as follows:

Approved	257,748,285	votes	or	100.0000%
Disapproved	-	votes	or	-
Abstained	-	votes	or	-
Voided Ballots	-	votes	or	-

Agenda item 9 **Other Matters (if any)**

The Company Secretary informed the Meeting that this agenda is set forth in the Shareholders' Meeting for shareholders to ask questions, discuss and/or give recommendations to the Board of Directors and/or the management of the Company (if any). Therefore, no items will be approved and no voting will take place during this agenda.

Then, allowed shareholders to inquiries or express opinions and asked **the MC** to explain the process for asking a question. Questions and suggestions that were raised subsequently were summarized as follows.

None of shareholders inquired or express opinions, **the Chairman** thanked shareholders and every representative for their time at today's meeting and adjourned the meeting.

Meeting adjourned at 11:10 pm.

Signed Chairman of the Meeting
(Mr. Amnuay Preemonwong)

Signed Company Secretary /
(Miss Tasanun Chuiklom) Meeting Recorder